Eli Lilly (LLY) valuation

Run six valuation models on Eli Lilly with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

LLY
LLY

Eli Lilly

LLY · Healthcare

Current price

1.416,53 USD

𝕏 Share on X
You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
1.26 T USD
PE (TTM | NTM | +1y)
45.98 | 27.89 | 27.89
Price / Sales
14.59
EV / EBITDA
28.39
Price / Book
31.35

Cash flow

FCF yield(10.49 / 1416.53)
+0.74%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
+31.9%
Operating margin
+51.25%
Quarterly earnings (YoY)
—
Quarterly revenue (YoY)
—

Balance

Cash
4.89 B USD
Debt
49.50 B USD
Net position
-44.62 B USD

Dividend

Dividend yield
+0.48%
Payout ratio
+21.71%
Next payout
12/10/2026

Price (5 years)

+443.39%
1.44 K USD

What the market paid for its earnings

P/E (TTM)46.0×
50100Its own median 63.8×Its own mean 70.4×20212026

Each week's price divided by the earnings per share already reported by that date — four quarters where a company reports them, its last full year otherwise. Loss-making weeks are not drawn. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What the market paid for the year ahead

Forward P/E27.9×
204060Its own median 33.5×Its own mean 35.3×20212026

Each week's price divided by the earnings of the year still ahead of it. Those years have since happened, so this is the multiple paid against the figure that landed: nobody records what analysts expected at the time. The most recent stretch uses today's consensus. Both lines are the company's own: the median is where it traded in half its weeks, the mean is where the extremes pull that average to. A mean well above the median means the high ratings were occasional rather than usual.

What analysts expect

Consensus revenue and earnings per share for the periods not yet reported.

Revenue forecast

ReportedEstimate
010B20BQ4 25: 19.29 B USDQ4 25Q1 26: 19.80 B USDQ1 26Q2 26: 22.97 B USDQ2 26Q3 26: 24.40 B USDQ3 26Q4 26 · Estimate: 24.70 B USD (23.82 B USD – 25.80 B USD)Q4 26Q1 27 · Estimate: 23.55 B USD (22.64 B USD – 24.60 B USD)Q1 27USD

Consensus of 15 analysts for Q4 26 · +28.02% year on year

EPS forecast

ReportedEstimate
0510Q4 25: 7.54 · expected 6.91 (+9.14%)Q4 25Q1 26: 8.55 · expected 6.79 (+25.9%)Q1 26Q2 26: 8.38 · expected 6.58 (+27.27%)Q2 26Q3 26: 7.48 · expected 6.35 (+17.88%)Q3 26Q4 26 · Estimate: 11.25 (10.40 – 12.42)Q4 26Q1 27 · Estimate: 10.94 (10.31 – 11.63)Q1 27

Consensus of 17 analysts for Q4 26 · +49.22% year on year · adjusted earnings

Analyst consensus from Yahoo Finance. The dashed bar is the average and the whisker runs from the lowest analyst to the highest. On periods already reported, the green or red line marks what had been expected: below the bar means the company beat it. EPS is measured on an adjusted basis, which is what analysts forecast against and is not the accounting profit in the statements.

Revenue

estimate
010B20BQ3 23: 9.50 B USDQ3 23Q4 23: 9.35 B USDQ1 24: 8.77 B USDQ1 24Q2 24: 11.30 B USDQ3 24: 11.44 B USDQ3 24Q3 25: 17.60 B USDQ4 25: 19.29 B USDQ4 25Q1 26: 19.80 B USDQ2 26: 22.97 B USDQ3 26: 24.40 B USDQ3 26Q4 26 · estimate: 24.70 B USDQ4 26USD

EBITDA

05B10BQ3 23: 962.80 M USDQ3 23Q4 23: 3.03 B USDQ1 24: 3.12 B USDQ1 24Q2 24: 4.12 B USDQ3 24: 2.25 B USDQ3 24Q3 25: 8.86 B USDQ4 25: 12.14 B USDQ4 25Q1 26: 10.29 B USDQ2 26: 12.99 B USDQ3 26: 13.64 B USDQ3 26USD

Net income

02B4B6BQ3 23: -57.40 M USDQ3 23Q4 23: 2.19 B USDQ1 24: 2.24 B USDQ1 24Q2 24: 2.97 B USDQ3 24: 970.30 M USDQ3 24Q3 25: 5.58 B USDQ4 25: 6.64 B USDQ4 25Q1 26: 7.40 B USDQ2 26: 7.10 B USDQ3 26: 6.45 B USDQ3 26USD

Free cash flow

02B4B6BQ1 24: 179.70 M USDQ1 24Q3 25: 6.03 B USDQ3 25Q4 25: 254.20 M USDQ4 25Q1 26: 2.80 B USDQ1 26Q2 26: 4.48 B USDQ2 26Q3 26: 4.16 B USDQ3 26USD

EPS

02.557.5Q3 23: -0.06Q3 23Q4 23: 2.42Q1 24: 2.48Q1 24Q2 24: 3.28Q3 24: 1.07Q3 24Q3 25: 6.21Q4 25: 7.39Q4 25Q1 26: 8.26Q2 26: 7.94Q3 26: 7.22Q3 26

Cash & debt

CashDebt
020B40BQ3 23 · Cash: 2.38 B USDQ3 23Q4 23 · Cash: 2.82 B USDQ1 24 · Cash: 2.46 B USDQ1 24Q2 24 · Cash: 3.22 B USDQ3 24 · Cash: 3.37 B USDQ3 24Q3 25 · Cash: 9.79 B USDQ3 25 · Debt: 42.51 B USDQ4 25 · Cash: 7.27 B USDQ4 25 · Debt: 42.50 B USDQ4 25Q1 26 · Cash: 5.28 B USDQ1 26 · Debt: 43.37 B USDQ2 26 · Cash: 8.95 B USDQ2 26 · Debt: 54.91 B USDQ3 26 · Cash: 4.89 B USDQ3 26 · Debt: 49.50 B USDQ3 26USD

Return of capital

DividendsBuybacks
01B2B3BQ3 23 · Dividends: 1.02 B USDQ3 23 · Buybacks: 0.00 USDQ3 23Q4 23 · Dividends: 1.02 B USDQ4 23 · Buybacks: 0.00 USDQ1 24 · Dividends: 1.17 B USDQ1 24 · Buybacks: 0.00 USDQ1 24Q2 24 · Dividends: 1.17 B USDQ2 24 · Buybacks: 0.00 USDQ3 24 · Dividends: 1.17 B USDQ3 24 · Buybacks: 446.10 M USDQ3 24Q3 25 · Dividends: 1.35 B USDQ3 25 · Buybacks: 708.00 M USDQ4 25 · Dividends: 1.35 B USDQ4 25 · Buybacks: 1.51 B USDQ4 25Q1 26 · Dividends: 1.55 B USDQ1 26 · Buybacks: 2.36 B USDQ2 26 · Dividends: 1.55 B USDQ2 26 · Buybacks: 1.60 B USDQ3 26 · Dividends: 1.54 B USDQ3 26 · Buybacks: 377.00 M USDQ3 26USD

Stock-based compensation

0100M200MQ3 23: 215.60 M USDQ3 23Q4 23: 120.70 M USDQ1 24: 159.40 M USDQ1 24Q2 24: 211.10 M USDQ3 24: 133.20 M USDQ3 24Q3 25: 151.00 M USDQ4 25: 136.10 M USDQ4 25Q1 26: 161.00 M USDQ2 26: 201.00 M USDQ3 26: 200.00 M USDQ3 26USD

Operating expenses

R&DSG&A
02B4B6BQ3 23 · SG&A: 1.80 B USDQ3 23Q4 23 · SG&A: 1.93 B USDQ1 24 · SG&A: 1.95 B USDQ1 24Q2 24 · SG&A: 2.12 B USDQ3 24 · SG&A: 2.10 B USDQ3 24Q3 25 · R&D: 3.47 B USDQ3 25 · SG&A: 2.74 B USDQ4 25 · R&D: 3.80 B USDQ4 25 · SG&A: 3.13 B USDQ4 25Q1 26 · R&D: 3.51 B USDQ1 26 · SG&A: 2.93 B USDQ2 26 · R&D: 3.82 B USDQ2 26 · SG&A: 3.43 B USDQ3 26 · R&D: 4.25 B USDQ3 26 · SG&A: 3.13 B USDQ3 26USD

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Popular companies